1. Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer 
Thomas W Rice, MD, David J Adelstein, MD, Jay P Ciezki, MD, Mark E Becker, MD, Lisa A Rybicki, MS, Carol F Farver, MD, Marjorie A Larto, RN, Eugene H Blackstone, MD 
The Annals of Thoracic Surgery 
Volume 66, Issue 6, Pages (December 1998)
DOI: /S (98)

2. Fig 1
Treatment schema for short-course neoadjuvant therapy for stage III non-small-cell lung carcinoma. (CDDP = cisplatin; RT = radiation therapy.)
The Annals of Thoracic Surgery  , DOI: ( /S (98) )

3. Fig 2
The Kaplan-Meier survival curve. The median survival is 22 months with a projected survival of 49% at 2 years. At 1 and 2 years, 70% confidence levels are depicted. The number of patients at risk at 1, 2, and 3 years is recorded in parentheses.
The Annals of Thoracic Surgery  , DOI: ( /S (98) )

4. Fig 3
The Kaplan-Meier survival for pathologic responders and nonresponders. At 1 and 2 years, 70% confidence levels are depicted. The number of patients at risk at 1, 2, and 3 years is recorded in parentheses.
The Annals of Thoracic Surgery  , DOI: ( /S (98) )

5. Fig 4
The Kaplan-Meier survival for patients downstaged to Stage 0, I, or II and those not downstaged (stage IIIA, IIIB, or IV). At 1 and 2 years, 70% confidence levels are depicted. The number of patients at risk at 1, 2, and 3 years is recorded in parentheses.
The Annals of Thoracic Surgery  , DOI: ( /S (98) )